WO1995016459A1 - Methode de superovulation dirigee des femelles bovines mises en anoestrus prolonge, methode de mise en anoestrus et kit de superovulation - Google Patents
Methode de superovulation dirigee des femelles bovines mises en anoestrus prolonge, methode de mise en anoestrus et kit de superovulation Download PDFInfo
- Publication number
- WO1995016459A1 WO1995016459A1 PCT/FR1994/001464 FR9401464W WO9516459A1 WO 1995016459 A1 WO1995016459 A1 WO 1995016459A1 FR 9401464 W FR9401464 W FR 9401464W WO 9516459 A1 WO9516459 A1 WO 9516459A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lhrh
- hormone
- formulation
- days
- fsh
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
Definitions
- the present invention relates to a method of supervised superovulation of bovine females after anestrus and also, in particular, to the specific method of anestrus of these animals. It also relates to a superovulation kit for female bovines.
- Each of them is formed by the simultaneous recruitment of several small diameter antral follicles which are detected as soon as their diameter is close to 4 mm. Their growth quickly reveals a dominant follicle, larger than the others, which can be ovulatory (dominant follicle of the 2nd or 3rd wave in the cycles of 2 or 3 waves respectively) or anovulatory (dominant follicle of the or the 2nd wave in the cycles with 2 or 3 waves respectively).
- the other follicles, or overlapped follicles differ from the previous one by stopping their growth, which is followed by their regression.
- the inhibitory action of the dominant follicle present on the superovulation response to FSH treatment has been clearly demonstrated (LA.
- the superovulation treatments carried out on the 1st wave of follicles only make it possible to obtain a number of ovulations lower than that which is obtained by the application of the treatment on the other waves.
- the comparison of the results obtained on the 1st wave (GP Adams et al., Anim. Reprod. Sci., 1993, 30, 259-71) are clearly lower than those obtained by intervening on the 2nd wave (LA Guilbaut et al ., J. Reprod. Fert., 1991, 91, 81-89) between days 7 and 12 of the cycle. It shows that the application of the superovulation treatment on the 1st wave cannot bring any advantage in current practice although the follicular development of the 1st wave is a preferred physiological study model.
- FSH appears after the selection period at the time of basal FSH secretion and is believed to be due to the direct inhibitory action of growing follicles.
- hCG chorionic gonadotropin
- the subject of the invention is therefore a method of directed superovulation of bovine females, comprising the following steps:
- the proposed superovulation method therefore consists in deciding when to recruit the follicles, to stimulate their growth by treatment with the hormone.
- FSH gonadotrope associated or not with LH to isolate the growing follicles from any indirect inhibitory or stimulatory action originating from the ovarian action on the hypothalamic-pituitary-ovarian axis to suppress or greatly reduce the divergence between ovulatory and non-ovulatory follicles and induce ovulation by providing, at a determined time in the development of follicles, LH or hCG in sufficient quantity and for a sufficient time.
- the new mode of secretion of gonadotropic hormones has resulted in the suppression of oestrus cycles.
- This state of anoestrus is controlled, after the disappearance of the luteal phase existing at the time of application of the treatment (preferred time), by maintaining the level of plasma progesterone below the detection threshold. Treatment preferably begins at the start of this luteal phase.
- Desensitization of the pituitary gland to the action of the endogenous LHRH hormone can be obtained in particular either by the administration of a LHRH agonist analogue at high (supraphysiological) and continuous dose, or by the administration of an analogue LHRH antagonist, during the time necessary for the establishment and maintenance of the deep anestrus allowing the application of the successive treatment or treatments of superovulation, fertilization of the oocytes by artificial insemination and harvesting of the embryos, which will be followed by their transfer before or after freezing.
- These last three techniques are the usual techniques used by people specialized in artificial insemination operations, harvesting and transfer of embryos.
- formulations allowing the continuous release of the LHRH analog over a duration which determines the duration of the deep anestrus phase.
- LHRH agonist analogue it is necessary to understand as is the custom any molecule possessing the biological properties of natural LHRH, that is to say in particular action on the pituitary gland triggering a secretion of LH and FSH. It can also be the LHRH itself.
- LHRH agonist analogues are known to specialists today and it is therefore not within the scope of this request to cite them all. They can be of natural, recombinant or synthetic origin, that is to say obtained by complete chemical synthesis or by chemical modification of a natural molecule, for example by substitution of amino acids and / or modification of the carboxyterminal or aminoterminal ends.
- the invention preferably uses the analogue D.Trp 6 -LHRH (patent FR-A-2 313 940) or Des-Gly-D.Trp 6 -LHRH ethylamide (patent FR-A-2 397 192).
- the effect sought with the agonist is a saturation of the LHRH receptors that lasts throughout the chosen period of deep anestrus.
- the agonist is therefore administered so that, throughout the period of administration, it is in supraphysiological concentration in the blood, which means that the agonist concentration remains at a level always higher than the peaks of secretion of endogenous LHRH by l 'hypothalamus. This is the application to the pituitary gland of the well-known phenomenon of desensitization (called "downregulation" of LHRH receptors by the Anglo-Saxons).
- the dosage depends on the formulation which itself defines the duration of release. We cannot in fact define the minimum plasma content required for analog because, below a certain threshold, techniques no longer allow the actual concentration of analog to be detected and measured.
- the desired deep anestrus effect is characterized specifically by a stop in follicular development during the entire deep anestrus phase, this state being able to be confirmed in particular by ultrasound examinations. In particular, the ultrasound examination will essentially reveal the existence of follicles of diameter not not exceeding approximately 14 mm, preferably approximately 10 mm.
- the doses of agonists may be as follows: - for a release formulation of the order of 40 to 50 days: from 15 to 150 mg, in particular from 25 to 100 mg.
- a release formulation of the order of 85 to 100 days from 30 to 300 mg, in particular from 50 to 200 mg, or approximately twice the doses chosen for the shorter release.
- the minimum doses may be increased or decreased for animals whose weight deviates appreciably from the arbitrary average of 500 kg (respectively greater than 500 kg and less than 500 kg)
- the animal is administered a dose of this LHRH agonist of between 40 and 150 mg approximately and preferably approximately 50 and 100 mg.
- the dose can be between 100 and 300 mg approximately.
- Des-Gly-D.Trp 6 -LHRH ethylamide has been shown to be effective at doses slightly lower than those of the previous one; in particular, efficacy has been demonstrated at doses of 16.7, 33.7 and 50.1 mg of agonist with a release time of the order of 40 to 50 days approximately.
- the effective dose under these conditions is greater than 16-17 mg and even approximately 15 mg, preferably greater than 25 mg, in particular between 30 and 40 mg approximately and more particularly of the order of 33 or 34 mg, agonist for a formulation with a release time of the order of 40 to 50 days.
- the effective dose for a release formulation of approximately 85 to 100 days preferably corresponds approximately to twice the dose for 40 to 50 days.
- a dose greater than 30 mg may therefore be administered in particular, in particular a dose between 60 and 80 mg.
- the invention also provides for the use of LHRH antagonist analogues.
- LHRH antagonist analogues This is what is commonly known as molecules opposing the action of endogenous LHRH by their attachment to receptors specific to this hormone. Their action is faster than that of agonists and requires concentration to block the receptors on the duration chosen for deep anestrus.
- the antagonists do not cause a short-term prime stimulation effect on the secretion of LH and FSH, as is the case with the agonists before obtaining the state of desensitization.
- LHRH LHRH.
- Use may in particular be made of the antagonists described in international patent application WO 92/19651 (agonists according to the sequences SEQ ID NO: 1 and NO: 2 described in this application) and the agonists ORG 30850 (GHJ Deckers et al., J. Steroid Biochem. Molec. Biol., Vol. 42, 705 - 712, 1992), Antide (K. Wallen et al., Physiology & Behavior, vol. 50, 429-435, Pergamon Press pic, 1991). See also in V.J. Cseraus et al., P.N.A.S. USA, vol. 89, 5759-5763, 1992.
- GnRH has already been described in cattle for a different purpose from that which is the subject of the invention.
- the administrations of synthetic GnRH to the prepubescent heifer (SE Dodson et al., J. Reprod. Fertil., 1988, 82, 526-538) or of busereiine (F. Grassalli et al., Anim. Reprod. Sci. , 1993, 32, 153-161) are performed at low doses, are limited to 10-15 days, and are intended to trigger early ovulation.
- FSH FSH
- This parenteral supply is carried out by administration at least twice a day, at regular intervals, or by a continuous release system (for example as described for the LHRH analog).
- This intake is preferably maintained for 4 to 7 days.
- Administration of LH or hCG is preferably carried out for about 1 to 2 days, and preferably begins on the last day of administration of FSH. LH or hCG should generally be avoided during heat.
- the administration will be carried out when the size of the follicles is at least 14 mm, in particular of the order of 14-15 mm.
- the LH used is either an extraction hormone, porcine, ovine or bovine or equine or a recombinant hormone.
- the subject of the invention is also the method itself, as defined above, which consists in administering to the animal an analog, agonist or antagonist, of LHRH so as to desensitize the pituitary gland to the action of endogenous LHRH, to obtain a deep anestrus.
- desensitization of the pituitary gland to endogenous LHRH can also be achieved by anti-LHRH immunoneutralization by active or passive route.
- the invention also relates to a superovulation kit for bovine females, comprising, separately, a continuous-release formulation comprising as active ingredient an LHRH analog, a formulation comprising as active ingredient FSH hormone and a formulation comprising an active principle chosen from the group consisting of hormone LH and hormone hCG.
- a superovulation kit for bovine females comprising, separately, a continuous-release formulation comprising as active ingredient an LHRH analog, a formulation comprising as active ingredient FSH hormone and a formulation comprising an active principle chosen from the group consisting of hormone LH and hormone hCG.
- the formulations are in particular in accordance with what has been described above.
- FIG. 1 a graph presenting, for cow no 1, the profile of the plasma concentration of progesterone, determined by radioimmunoassay, after injection on day 0 of a PLG 50:50 / D.Trp 6 -LHRH formulation (150 mg of agonist analog) having a release profile of the order of 40 days, the plateau which corresponds to the absence of detection of plasma progesterone representing the phase of deep anestrus - this graph corresponds to table 1;
- FIG. 5 a graph presenting the profile of the plasma progesterone concentration of a control cow which has not received an LHRH analog formulation - the cycles are proceeding normally.
- fatty substances represented in particular by fatty acids and esters of fatty acid or of polyethylene glycol.
- the first formulation method uses degradable polymers from the poly (lactide-glycolide) and poly (lactic-glycolic) (PLG) family. These polymers have a very satisfactory biocompatibility and have the capacity to hydrolyse to generate natural components, lactic acid and glycolic acid.
- the rate of hydrolysis of these polymers is adjustable as a function essentially of the ratio of the lactide and glycolide comonomers, of the molecular mass of the polymers, and of the lactide isomers used. This speed is maximum when the ratio is equal to 50/50, then it decreases when the proportion of lactide increases. This property is used to modulate the release time of the LHRH analogs from a dosage form produced with these polymers.
- LHRH analogs and more particularly LHRH agonists are peptides insoluble in a PLG matrix. These compounds are generally present in the form of a microdispersion in the excipient PLG.
- the dosage form can be variable: films, implants or microspheres. The latter dosage form has the advantage of being easily injectable, after resuspension in a suitable liquid.
- the microencapsulation methods allowing this galenical form to be obtained are variable, essentially: microencapsulation by coacervation, by evaporation of solvent, and the spray-drying method. The microencapsulation method by solvent evaporation is described in Example 1.
- the release mechanisms of the LHRH agonist from the dosage form are varied:
- this mode of diffusion of an active principle dispersed in a hydrophobic polymer matrix is linked to the interconnection of the particles of active principle between them, this interconnected network itself being in contact with the external medium.
- the release of the active ingredient is linked to the gradual penetration of biological fluids into the network, allowing the active ingredient to dissolve and spread to the outside environment.
- This release mode is modulated quantitatively and over time by the proportion of active ingredient dispersed in the polymer matrix, the solubility of the active ingredient, its particle size.
- the hydrolysis of the polymer for example a PLG, splits the polymer chains into shorter, water-soluble fragments over time. This phenomenon induces an increase in hydrophilicity and in the porosity of the dosage form, allowing the penetration of biological fluids and the extraction of the active principle. This release mechanism is modulated over time by the rate of hydrolysis of the polymer and by the initial molecular weight of the polymer.
- 2nd phase diffusion phase linked to percolation, the release rate of which is controlled by the proportion of LHRH agonists used in the formulation of microspheres.
- the duration of this phase is controlled by the ratio of lactide / glycolide co-monomers, and by the initial molecular weight of the polymer. This phase is all the shorter as the lactide / glycolide ratio is close to 50/50 and the initial molecular weight of the polymer is low.
- 3rd phase release phase linked to the hydrolysis of the polymer, the duration of which is controlled essentially by the lactide / glycolide ratio. This duration can vary from about a month to more than a year. The release rate is generally higher than that of the previous phase.
- the three-phase release profile can be modified with the formulation parameters:
- the increase in the release rate during the 2nd phase is obtained by increasing the proportion of active ingredient in the formulation, the release kinetics tending towards a regularly decreasing profile over time.
- Non-triphasic, but relatively constant or regularly decreasing release profiles are also obtained with low molecular weight polymers, for example poly (DL lactide) with molecular weight of the order of 2000. These polymers can be used pure in the formulation, or previously mixed with polymers of higher molecular weight, then formulated.
- poly (DL lactide) with molecular weight of the order of 2000.
- the combination of the formulation parameters makes it possible to obtain durations and controlled release profiles.
- the total release time of an LHRH agonist can be adjusted to reach periods varying from a few days to more than a year.
- a second formulation method uses fatty substances, for example fatty acids or fatty acid esters, formulated as implants or microspheres with the active principle.
- fatty substances for example fatty acids or fatty acid esters, formulated as implants or microspheres with the active principle.
- the release mechanism of an agonist for example fatty acids or fatty acid esters, formulated as implants or microspheres with the active principle.
- the proportion of agonist incorporated into the formulation the duration of release decreases with the increase in the proportion of agonist incorporated.
- the HLB value Lipophilic Hydrophilic Balance of the lipid excipient: the increase for example from 1 to 5 of the HLB value of the lipid excipient makes it possible to reduce from 5 months to one week the total duration of release of a LHRH agonist incorporated into lipid implants.
- the measurement of the plasma concentrations of released D.Trp 6 -LHRH and of progesterone is carried out by radioimmunological method.
- the radioimmunoassay of plasma D.Trp 6 -LHRH is based on the principle of a competitive inhibition reaction between D.Trp 6 -LHRH labeled with 125 I in constant quantity and the standard D.Trp 6 -LHRH or that contained in the plasma samples, with respect to the binding sites of an anti-D.Trp 6 -LHRH serum.
- the amount of D.Trp 6 -LHRH is expressed in ng / ml of plasma.
- the radioimmunoassay of progesterone plasma is carried out by direct method using progesterone marked by the 25 I. It is based on a competitive inhibition reaction between the labeled progesterone in a constant quantity and the standard progesterone or that contained in plasma samples. The amount of progesterone is expressed in ng / ml of plasma.
- the desensitization treatment was applied to 4 cows using the LHRH agonist analog, D.Trp 6 -LHRH. This was incorporated into microspheres of lactic-glycolic copolymers which ensure a detectable plasma concentration in the bovine female for 40 days for a first formulation and 85-100 days for the second.
- This formulation allows the agonist D.Trp 6 -LHRH to be released for approximately 40 days at detectable levels in cows.
- 45 mg of a lyophilizate of D. Trp 6 -LHRH (trifluoroacetate) are weighed and then dispersed in a solution composed of 1455 mg of poly (DL lactide-glycolide) 50:50 with an inherent viscosity 0.4 dl / g, in 5 , 4 ml of dichloromethane with stirring.
- This solvent allows the fine dispersion of the lyophilisate and allows the polymer to dissolve.
- the dispersion is injected through a tube 2 mm in diameter into 450 ml of a solution of 1% polyvinyl alcohol in demineralized water at 25oC, with stirring of a propeller rotating at 700 revolutions per minute.
- Two drops of an anti-foam silicone emulsion are distributed, then the dichloromethane is evaporated by diffusion of compressed air into the mixture.
- the hardened microspheres are collected by vacuum filtration, washed with demineralized water and are then dried on a filter paper. Additional washing with 40 ml of trichloro 1,1,2 trifluoro 1,2,2 ethane eliminates the residual anti-foam silicone.
- the microspheres are dried, then stored at + 4oC.
- D.Trp 6 -LHRH The amount of D.Trp 6 -LHRH present in the microspheres is determined by an extraction method then assay in high performance liquid chromatography.
- microspheres equivalent to 150 mg of D.Trp 6 -LHRH incorporated is distributed in 2 syringes.
- the microspheres of each syringe are suspended in 20 ml of a viscous liquid composed of 2% carboxymethyl cellulose and 0.2% Tween 80 in solution in physiological water, then are injected by deep intramuscular route in the neckline.
- This formulation frees the agonist for approximately 85-100 days.
- the same method of preparation is adopted with a 65:35 poly (DL lactide-glycolide) polymer with an inherent viscosity 0.34 dl / g: 90 mg of a lyophilizate D. Trp 6 -LHRH are weighed and then dispersed in a compound solution. 1410 mg of poly (DL lactide-glycolide) 63:35 in 3 ml of dichloromethane, with stirring. The subsequent steps are identical to the previous description.
- microspheres based on lactic-glycolic copolymers were carried out at the start of the luteal phase. It resulted in an extension of the luteal phase on all animals, compared with the duration of the luteal phase of the previous cycle.
- progesterone secretion defined anoestrus in the absence of other examinations (ultrasound, LH and FSH assays).
- the end of the anestrus period is less precise and must occur a few days before the reappearance of progesterone.
- the ultrasound examination was limited to 2 observations at one week intervals at specific times during treatment, on the one hand towards the probable end of its effectiveness, one month after the disappearance of detectable traces of D.Trp 6 -LHRH in plasma, on the other hand during the stationary phase of treatment, marked by a stable concentration characteristic of the LHRH agonist.
- This anestrus could be classified into two very different states in one and the other moment, a deep anestrus during the phase corresponding to the demonstration in the plasma of the agonist, a light anestrus one month after the disappearance of plasma of D.Trp 6 -LHRH.
- Table 1 and Figures 1 and 2 relate to cows 1 and 4 having received short-term desensitization treatment (40 detectable days).
- the end of the luteal phase begins 21 days after administration at the start of the luteal phase for cows 1 and 4.
- the ultrasound examination was carried out 1 month after the disappearance of the measurable plasma D.Trp 6 -LHRH, i.e. 65 and 72 days for cow 1 and 58 and 65 days for cow 2 after administration of the microspheres; it led to the following observations (number of follicles F and diameter in mm) which reflect a slight anoestrus: a) Cow no 1 (1393)
- Table 2 and Figures 3 and 4 relate to cows 5 and 6 having received long-term desensitization treatment (D.Trp 6 -LHRH detectable in plasma for 86 and 103 days).
- the end of the luteal phase begins, for cow 5, 15 days, and for cow 6, 25 days, after administration at the start of the luteal phase.
- Table 3 and Figure 5 relate to the progesterone measurements made on a control cow (1398).
- the desensitization treatment was applied to 6 cows using the LHRH agonist analogue, D.Trp 6 -LHRH.
- This stage can be triggered at any time during the deep anestrus phase.
- the time necessary to reach the embryos and their harvest since it is preferable that all operations, including the harvesting of the embryos, be carried out inside the deep anestrus phase. From the start of FSH treatment, it takes around 18 to 21 days until the embryos are collected. For the formulations used during the tests described above, the period of establishment of the deep anestrus is on average:
- This period is easy to determine for each formulation during an anestrus test and the monitoring of the evolution of the progesterone concentration (and ultrasound examination and possibly FSH measurement to confirm the state of deep anestrus ).
- the animal is administered FSH hormone, possibly in the presence of the LH hormone.
- - FSH extraction hormone preferably of porcine, ovine (or bovine or equine) origin, had recombinant hormone;
- - daily dosage depending on the origin of the hormone from 30 to 300 ⁇ g / d, preferably between 80 and 140 ⁇ g / d approximately, for example of the order of 125 ⁇ g / d.
- Duration of treatment 4 to 7 days, the objective being to obtain follicles of approximately 14-15 mm.
- - dose from 2 to 6 mg / day for LH or from 3,000 to 6,000 IU / day for hCG.
- a continuous release formulation can be used.
- This treatment triggers ovulation.
- estrus preceding the treatment can be synchronized (which is optional) by methods well known to specialists.
- the observation of the ovaries is recorded on videotape. It is performed daily from the detection of heat that precedes the pituitary desensitization treatment until the end of the superovulation treatment.
- the hormones FSH, LH and progesterone were measured:
- LH 6 times a day, every hour between 8 and 12 hours from the day before the agonist's injection until the start of superovulation treatment.
- FSH 2 times a day, at 8 and 9 a.m., from the day before the agonist's injection until the start of superovulation treatment. The day of the injection of the agonist, 5 samples were taken, every hour between 8 and
- Progesterone 1 time per day from the day before the agonist's injection until the end of the superovulation treatment. The animals were their own control in an oestrian cycle preceding the treatment.
- the first folliculogenesis stimulation treatment using the Stimufol product (sold by RHONE MERIEUX, FRANCE; composition: FSH porcine 500 ⁇ g and LH porcine 100 ⁇ g per bottle, to be taken up in a volume of 10 ml) started 10 days after the disappearance of the last follicle with a diameter greater than 10 mm and was carried out under the usual conditions of a superovulation treatment at constant daily dose. The dosage used was different depending on the animals. Stimufol injections were given twice a day by intramuscular injection and were spaced 10 to 12 hours apart.
- prostaglandins Prosolvin 3 ml
- Stimufol treatment was stopped at the onset of heat, at the earliest after the 8th injection.
- the ovulatory injection of purified porcine LH or hCG was carried out at the time of heat, at the earliest 12 hours after the 8th injection of Stimufol, or after their appearance on the criterion of a follicular size at least equal to 14 mm .
- the average concentrations of LH between D4 and D14 of the cycle on the same animals do not differ from those which are measured after treatment; only the standard error is greater before treatment and reflects fluctuations in secretion in the untreated (0.07 - 0.139 ng / ml compared to 0.015 - 0.022 ng / ml).
- the number of follicles from the size of 5 to 7.5 mm is greater than or equal to 10.
- the average size of the follicles ranges from 11.9 to 15.9 mm depending on the animal.
- Ovulation induction was only effective when it occurred in follicles 14-15 mm in size. Performed at the time of heat on follicles smaller in size, it was not effective.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95903834A EP0734266A1 (fr) | 1993-12-16 | 1994-12-14 | Methode de superovulation dirigee des femelles bovines mises en anoestrus prolonge, methode de mise en anoestrus et kit de superovulation |
AU12754/95A AU1275495A (en) | 1993-12-16 | 1994-12-14 | Controlled superovulation method for female cattle undergoing prolonged anoestrus, anoestruation method and superovulation kit |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR93/15171 | 1993-12-16 | ||
FR9315171A FR2713933B1 (fr) | 1993-12-16 | 1993-12-16 | Méthode de superovulation des femelles bovines, méthode de mise en anoestrus et kit approprié. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995016459A1 true WO1995016459A1 (fr) | 1995-06-22 |
Family
ID=9454026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1994/001464 WO1995016459A1 (fr) | 1993-12-16 | 1994-12-14 | Methode de superovulation dirigee des femelles bovines mises en anoestrus prolonge, methode de mise en anoestrus et kit de superovulation |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0734266A1 (fr) |
AU (1) | AU1275495A (fr) |
CA (1) | CA2178954A1 (fr) |
FR (1) | FR2713933B1 (fr) |
WO (1) | WO1995016459A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2849380A1 (fr) * | 2002-12-27 | 2004-07-02 | Ernest Loumaye | NOUVELLE UTILISATION D'UN AGONISTE DU GnRH |
CN102168136A (zh) * | 2011-02-11 | 2011-08-31 | 中国农业大学 | 中国荷斯坦奶牛lhcgr基因作为分子标记的应用 |
US11376220B2 (en) | 2017-06-30 | 2022-07-05 | Therio, LLC | Single-injection methods and formulations to induce and control multiple ovarian follicles in bovine, caprine, ovine, camelid and other female animals |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2313940A1 (fr) * | 1975-06-12 | 1977-01-07 | Schally Andrew | Nouveaux peptides et leur preparation |
GB2001077A (en) * | 1977-07-14 | 1979-01-24 | Salk Inst For Biological Studi | Peptide which inhibits gonadal function |
EP0052510A2 (fr) * | 1980-11-18 | 1982-05-26 | Syntex (U.S.A.) Inc. | Microencapsulation de polypeptides hydrosolubles |
EP0161063A1 (fr) * | 1984-04-03 | 1985-11-13 | Serono Laboratories, Inc. | Méthode pour induire l'ovulation |
WO1990014839A1 (fr) * | 1989-06-02 | 1990-12-13 | Novo Nordisk A/S | Procede de traitement de la sterilite et agent utilise dans le procede |
EP0566135A1 (fr) * | 1992-04-17 | 1993-10-20 | Takeda Chemical Industries, Ltd. | Composition transmucosale contenant un peptide et un dérivé de la cytidine |
-
1993
- 1993-12-16 FR FR9315171A patent/FR2713933B1/fr not_active Expired - Fee Related
-
1994
- 1994-12-14 AU AU12754/95A patent/AU1275495A/en not_active Abandoned
- 1994-12-14 EP EP95903834A patent/EP0734266A1/fr not_active Withdrawn
- 1994-12-14 CA CA 2178954 patent/CA2178954A1/fr not_active Abandoned
- 1994-12-14 WO PCT/FR1994/001464 patent/WO1995016459A1/fr not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2313940A1 (fr) * | 1975-06-12 | 1977-01-07 | Schally Andrew | Nouveaux peptides et leur preparation |
GB2001077A (en) * | 1977-07-14 | 1979-01-24 | Salk Inst For Biological Studi | Peptide which inhibits gonadal function |
EP0052510A2 (fr) * | 1980-11-18 | 1982-05-26 | Syntex (U.S.A.) Inc. | Microencapsulation de polypeptides hydrosolubles |
EP0161063A1 (fr) * | 1984-04-03 | 1985-11-13 | Serono Laboratories, Inc. | Méthode pour induire l'ovulation |
WO1990014839A1 (fr) * | 1989-06-02 | 1990-12-13 | Novo Nordisk A/S | Procede de traitement de la sterilite et agent utilise dans le procede |
EP0566135A1 (fr) * | 1992-04-17 | 1993-10-20 | Takeda Chemical Industries, Ltd. | Composition transmucosale contenant un peptide et un dérivé de la cytidine |
Non-Patent Citations (1)
Title |
---|
MCNEILLY A.S. ET AL: "Luteinizing hormone pulses, follicle-stimulating hormone and control of follicle selection in sheep", JOURNAL OF REPRODUCTION AND FERTILITY SUPPLEMENT, vol. 45, 1992, OXFORD, pages 5 - 19 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2849380A1 (fr) * | 2002-12-27 | 2004-07-02 | Ernest Loumaye | NOUVELLE UTILISATION D'UN AGONISTE DU GnRH |
WO2004058269A1 (fr) * | 2002-12-27 | 2004-07-15 | Ernest Loumaye | Utilisation d'agonistes gnrh de stimulation de la phase luteinique dans le traitement de l'infertilite |
US7671027B2 (en) | 2002-12-27 | 2010-03-02 | Preglem S.A. | Use of GnRH agonists to support the luteal phase during infertility treatment |
CN102168136A (zh) * | 2011-02-11 | 2011-08-31 | 中国农业大学 | 中国荷斯坦奶牛lhcgr基因作为分子标记的应用 |
US11376220B2 (en) | 2017-06-30 | 2022-07-05 | Therio, LLC | Single-injection methods and formulations to induce and control multiple ovarian follicles in bovine, caprine, ovine, camelid and other female animals |
US11964053B2 (en) | 2017-06-30 | 2024-04-23 | Therio, LLC | Single-injection methods and formulations to induce and control multiple ovarian follicles in bovine, caprine, ovine, camelid and other female animals |
Also Published As
Publication number | Publication date |
---|---|
CA2178954A1 (fr) | 1995-06-22 |
FR2713933A1 (fr) | 1995-06-23 |
FR2713933B1 (fr) | 1996-02-02 |
EP0734266A1 (fr) | 1996-10-02 |
AU1275495A (en) | 1995-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Messinis | Ovarian feedback, mechanism of action and possible clinical implications | |
JP5107725B2 (ja) | GnRH類似体製剤 | |
Concannon | Endocrinologic control of normal canine ovarian function | |
Lin et al. | Differential regulation of gonadotropins (FSH and LH) and growth hormone (GH) by neuroendocrine, endocrine, and paracrine factors in the zebrafish—an in vitro approach | |
Reubi | A somatostatin analogue inhibits chondrosarcoma and insulinoma tumour growth | |
Tacon et al. | Effect of egg deprivation on sex steroids, gonadotropin, prolactin, and growth hormone profiles during the reproductive cycle of the mouthbrooding cichlid fish Oreochromis niloticus | |
Hoffmann et al. | Reproductive endocrinology of bitches | |
FR2849380A1 (fr) | NOUVELLE UTILISATION D'UN AGONISTE DU GnRH | |
Bergfeld et al. | Pituitary function, ovarian follicular growth, and plasma concentrations of 17β-estradiol and progesterone in prepubertal heifers during and after treatment with the luteinizing hormone-releasing hormone agonist deslorelin | |
Peters | Hormonal control of the bovine oestrous cycle. I. The natural cycle | |
WO2007062483A1 (fr) | Formulation visant à augmenter le taux de grossesse | |
Prevot et al. | The polygamous GnRH neuron: astrocytic and tanycytic communication with a neuroendocrine neuronal population | |
EP0734266A1 (fr) | Methode de superovulation dirigee des femelles bovines mises en anoestrus prolonge, methode de mise en anoestrus et kit de superovulation | |
Murphy | Precocious induction of luteal activation and termination of delayed implantation in mink with the dopamine antagonist pimozide | |
Holloway et al. | The Effects ofN-Methyl-d, l-aspartate and Gonadotropin-Releasing Hormone onin VitroGrowth Hormone Release in Steroid-Primed Immature Rainbow Trout, Oncorhynchus mykiss | |
EP1680139B1 (fr) | Utilisation de la somatostatine ou d'un de ses analogues pour preparer un medicament destine a reguler la reserve folliculaire ovarienne chez la femme non menopausee | |
Agu et al. | Evidence for dopaminergic regulation of prolactin and a luteotropic complex in the ferret | |
WILSON et al. | Concentrations of corticosterone and luteinizing hormone in plasma during the ovulatory cycle of the domestic hen and after the administration of gonadal steroids | |
Kawate et al. | Roles of pulsatile release of LH in the development and maintenance of corpus luteum function in the goat | |
Knobil et al. | The physiology of the adenohypophyseal hormones | |
Diaz et al. | Effects of ageing and exogenous melatonin on pituitary responsiveness to GnRH in rats | |
Helmond et al. | Strength and duration characteristics of the facilitory and inhibitory effects of progesterone on the estrogen-induced gonadotropin surge in the female rhesus monkey | |
De Gier et al. | Physiology of the canine anoestrus and methods for manipulation of its length | |
Chyb et al. | Post-ovulatory secretion of pituitary gonadotropins GtH I and GtH II in the rainbow trout (Oncorhynchus mykiss): regulation by steroids and possible role of non-steroidal gonadal factors | |
JP3112172B2 (ja) | 多嚢胞卵巣疾病の治療 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BR CA CH DE DK ES GB NL NZ PT RU SE US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1995903834 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2178954 Country of ref document: CA Ref document number: 277508 Country of ref document: NZ |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1995903834 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995903834 Country of ref document: EP |